Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Braveheart Bio, Inc. (BRVE) Stock · SELL | LOPJLB

Braveheart Bio, Inc. (BRVE)

Healthcare · Biotechnology · NASDAQ · US

$19.79-7.31%Close

SELL

BRVE▼ SELL

$19.79-7.31%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Short interest · FINRA settlement 2026-09-15

Market cap: $1.4B
Beta: 0.00
Shares short: 2.5M

Days to cover: 7.5
SI change: +76.2%

1W: -11.41%
1M: -25.99%

vs SPY 1W: -13.36%
vs SPY 1M: -27.40%

Industry peers

FMP comparable companies · ranked by market cap

BBIOSELLBridgeBio Pharma, Inc.$13.1BRECOVERYQ 18$66.96+1.24%
CYTKSELLCytokinetics, Incorporated$7.6BCRISISQ 9$61.35-2.15%
KARDSELLKardigan, Inc.$1.2BQ -46$13.49-11.48%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Employees: 49
Headquarters: US
Founded: 2026
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 70.7M

braveheart.bio ↗

Key executives

Travis Murdoch — CEO, President & Director

Michele A. Anderson — Chief Development Officer

Emil deGoma — Chief Medical Officer

SEC filings

EDGAR · CIK 21315240 · BRVE

All filings
10-K
10-Q
8-K
Form 4

Analyst consensus

L $40.00Avg $45.25H $48.00

Target$45.25+128.65%

Last$19.79

Company news

defenseworld.net · 6d ago

Braveheart Bio (NASDAQ:BRVE) Stock Falls 7.3% – Here’s What Happened

globenewswire.com · 21d ago

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

globenewswire.com · 29d ago

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

globenewswire.com · 36d ago

Braveheart Bio to Participate in Cantor Global Healthcare Conference

fool.com · 58d ago

Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?

fool.com · 58d ago

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

fool.com · 58d ago

Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?

defenseworld.net · 59d ago

Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock

defenseworld.net · 59d ago

Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock

globenewswire.com · 61d ago

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

globenewswire.com · 63d ago

Braveheart Bio Announces Pricing of Upsized Initial Public Offering

seekingalpha.com · 68d ago

Braveheart Bio Readies $300 Million IPO Plan

Market news & ticker search · RSS for BRVE

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE